Applications

1617 – BRAF V600 testing to help determine eligibility for PBS access to Braftovi (encorafenib), in patients with metastatic colorectal cancer (Stage IV)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

The MBS item 73338 tests tumour tissue from a patient with metastatic colorectal cancer (stage IV) to determine if the requirements relating to rat sarcoma oncogene (RAS) gene mutation status for access to certain Pharmaceutical Benefits Scheme (PBS) medicines are fulfilled. This application seeks to amend item 73338 to include testing for BRAF V600 mutation status to determine eligibility for PBS access to encorafenib for metastatic colorectal cancer.

Type: Co-dependent technology

Medical condition this application addresses

-

Meetings to consider this application

  • PASC meeting: 16 to 17 April 2020
  • ESC meeting: 11 to 12 February 2021
  • MSAC meeting: 31 March to 1 April 2021